WIN WIN BUY |
I'm in ;))) |
FOMO mode:) |
fatfish I was referencing other people's thoughts if you look higher up not mine I concur Deloittes will not be responsible etc
re
"mmmmmmm don't quite know what you're referring to, can't imagine deloittes will be responsible for anything, unless they fraudulently fudge the figures" |
Traders are seeing very good value at this level again, and the buying starts :) |
 Results will be as below plus add 8m from court winning: Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations. Cash and debtFree cash flow in the Period rose 34% to £21.1m (FY22: £15.8m) and net debt reduction continued, falling to £92.4m at 31 December 2023 (31 December 2022: £102.0m). Group leverage2 (as at 31 December 2023) is expected to be significantly below that at 30 June 2023 (2.7x), and in-line with previous guidance.OutlookDemand for the Group's brands remains strong. Alliance's clear focus on the core Consumer Healthcare business, in addition to our well-established, scalable platform across EMEA, APAC and the US, is expected to deliver continued strong organic growth over the medium term. In 2024, the Board anticipates our Consumer Healthcare revenues to continue to grow above that of the broader Consumer Healthcare market, with stable Prescription Medicine revenues.In order to achieve our medium-term objectives, in 2024, the Board anticipates increased investment in sales and marketing, both directly and through the Group's distributors. The Company will also continue to deliver innovation in 2024 to further expand the reach of its brands. As a result, the Board anticipates that profits in 2024 will be in-line with 2023. |
Interest rates could start to come down next month, imho |
Results will be next week after the fat mouth has spoken ;)) |
seagreen
Time is till end of JUNE but accounting firm will be liable of any issues not company
mmmmmmm don't quite know what you're referring to, can't imagine deloittes will be responsible for anything, unless they fraudulently fudge the figures |
Single digit share price likely coming here. I'd salvage whatever you can before the drop. |
He will always appear on the risers boards and say taken profit to APH he's a desperate man very much under the water.. he was the same with Curry's |
Atomatic suspension looms unless they pull their fingers out
tyranosaurus
6 Jun '24 - 17:45 - 2904 of 2908
0 0 0
Listed companies must file within 6 months of their accounting reference date.
Let`s hope those Deloitte fellows know that.
Blackhorse23
6 Jun '24 - 17:49 - 2905 of 2908
0 0 0
Time is till end of JUNE but accounting firm will be liable of any issues not company |
He also posted on the Unilever site that he added APH again today. So , Blackhorse, answer the question, why are you making these claims on other BBs? How come you make multiple claims to selling those companies despite never claiming to have bought them previously? |
Sell by ncyt you appeared there saying you sold and bought here.. your making yourself look silly |
Hopefully soon we will see the results |
Time is till end of JUNE but accounting firm will be liable of any issues not company |
Listed companies must file within 6 months of their accounting reference date.
Let`s hope those Deloitte fellows know that. |
Sell while you can |
Moved money to ncyt |
Anyone bothered to contact Investor Relations?
Email
ir@allianceph.com |
What's looking good in here, your top ups can't be |
That's why they call u a liar.;)) |
What's your L2 saying?? |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
